Bristol-Myers warns diabetics about Tequin: FDA

	Tweet

Drugmaker Bristol-Myers Squibb is warning against the use of the antibiotic drug Tequin in diabetic patients after reports of several fatalities, the U.S. Food and Drug Administration said on Thursday.

The company is adding a contraindication warning for diabetics to the drug’s label as well as strengthening its warning that Tequin can cause both low and high blood sugar levels in patients, the FDA said.

The label will include warnings that patients who are older, have renal insufficiency and take other medicine that affects glucose levels can also be at risk, according to the agency.

"The FDA will continue monitoring Tequin’s safety to ensure that its benefits outweigh the risks to patients,” the FDA said in a statement.

Bristol-Myers spokesman Eric Miller said the company’s warning was prompted by reports of “serious cases” of high or low blood sugar among Tequin patients.

“Although most of these cases were reversible, very rare events of (high or low blood sugar) were life threatening and a few resulted in fatal outcomes,” Miller said.

The drugmaker sent letters to doctors about the changes in addition to alerting the FDA, Miller said.

Tequin is typically taken to treat patients with pneumonia, bronchitis, gonorrhea and other infections, such as those affecting the skin, urinary tract or kidneys. The drug had global sales of about $150 million last year, Miller said.

Since Tequin was approved in 1999, there have been “rare cases of life-threatening events” involving patients who took the drug, and while most of those incidents were reversible, there were a few fatal outcomes, the FDA said.

Risks of blood sugar swings were added to the warnings section of Tequin’s label in 2002.

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]